KR102960038B1 - 화학요법 불응성 암을 치료하기 위한 신규한 조합 방안 - Google Patents

화학요법 불응성 암을 치료하기 위한 신규한 조합 방안

Info

Publication number
KR102960038B1
KR102960038B1 KR1020217014387A KR20217014387A KR102960038B1 KR 102960038 B1 KR102960038 B1 KR 102960038B1 KR 1020217014387 A KR1020217014387 A KR 1020217014387A KR 20217014387 A KR20217014387 A KR 20217014387A KR 102960038 B1 KR102960038 B1 KR 102960038B1
Authority
KR
South Korea
Prior art keywords
cancer
pharmaceutical composition
compound
formula
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217014387A
Other languages
English (en)
Korean (ko)
Other versions
KR20210076951A (ko
Inventor
치앙 제이 리
Original Assignee
1글로브 바이오메디칼 씨오., 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 1글로브 바이오메디칼 씨오., 엘티디. filed Critical 1글로브 바이오메디칼 씨오., 엘티디.
Publication of KR20210076951A publication Critical patent/KR20210076951A/ko
Application granted granted Critical
Publication of KR102960038B1 publication Critical patent/KR102960038B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020217014387A 2018-10-12 2019-10-12 화학요법 불응성 암을 치료하기 위한 신규한 조합 방안 Active KR102960038B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201811195239.3 2018-10-12
CN201811195239 2018-10-12
PCT/CN2019/110904 WO2020074010A1 (zh) 2018-10-12 2019-10-12 治疗化疗难治性癌症的新联合用药方案

Publications (2)

Publication Number Publication Date
KR20210076951A KR20210076951A (ko) 2021-06-24
KR102960038B1 true KR102960038B1 (ko) 2026-04-30

Family

ID=70163618

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217014387A Active KR102960038B1 (ko) 2018-10-12 2019-10-12 화학요법 불응성 암을 치료하기 위한 신규한 조합 방안

Country Status (16)

Country Link
US (2) US12257227B2 (cg-RX-API-DMAC7.html)
EP (1) EP3865130A4 (cg-RX-API-DMAC7.html)
JP (2) JP7513286B2 (cg-RX-API-DMAC7.html)
KR (1) KR102960038B1 (cg-RX-API-DMAC7.html)
CN (2) CN120168498A (cg-RX-API-DMAC7.html)
AU (1) AU2019357933B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021006898A2 (cg-RX-API-DMAC7.html)
CA (1) CA3115869A1 (cg-RX-API-DMAC7.html)
EA (1) EA202190771A1 (cg-RX-API-DMAC7.html)
IL (1) IL282228B1 (cg-RX-API-DMAC7.html)
MX (1) MX2021004151A (cg-RX-API-DMAC7.html)
PH (1) PH12021550815A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202103707TA (cg-RX-API-DMAC7.html)
TW (1) TWI848990B (cg-RX-API-DMAC7.html)
WO (1) WO2020074010A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202102494B (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021004151A (es) * 2018-10-12 2021-09-08 1Globe Biomedical Co Ltd Nueva solución de combinación para el tratamiento contra cáncer refractario a la quimioterapia.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2190429B1 (en) 2007-09-10 2016-04-20 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
DK2547205T3 (da) 2010-03-19 2024-05-27 1Globe Biomedical Co Ltd Hidtil ukendte fremgangsmåder til målretning mod cancerstamceller
NZ602328A (en) 2010-03-19 2014-11-28 Boston Biomedical Inc Novel compounds and compositions for targeting cancer stem cells
CN103402993A (zh) 2011-03-04 2013-11-20 舟山海中洲新生药业有限公司 用于疾病治疗的4,9-二羟基-萘并[2,3-b] 呋喃新型酯
WO2013166618A1 (en) * 2012-05-08 2013-11-14 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
US20160030384A1 (en) 2013-04-09 2016-02-04 Boston Biomedical, Inc. 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
JP2018511643A (ja) * 2015-04-17 2018-04-26 ボストン バイオメディカル, インコーポレイテッド 癌を治療するための方法
WO2017132049A1 (en) * 2016-01-20 2017-08-03 Boston Biomedical, Inc. Methods for treating cancer
CN107766371B (zh) * 2016-08-19 2023-11-17 中兴通讯股份有限公司 一种文本信息分类方法及其装置
MX2021004151A (es) * 2018-10-12 2021-09-08 1Globe Biomedical Co Ltd Nueva solución de combinación para el tratamiento contra cáncer refractario a la quimioterapia.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Clinical Oncology. 2016. Vol. 34, No. 15_suppl(2016.05.20.) 1부.*

Also Published As

Publication number Publication date
IL282228A (en) 2021-05-31
US20210393571A1 (en) 2021-12-23
ZA202102494B (en) 2023-01-25
AU2019357933A1 (en) 2021-05-20
PH12021550815A1 (en) 2021-10-04
EA202190771A1 (ru) 2021-09-07
TWI848990B (zh) 2024-07-21
BR112021006898A2 (pt) 2021-07-20
CN113164438B (zh) 2025-03-18
US12257227B2 (en) 2025-03-25
JP2024123152A (ja) 2024-09-10
US20250235425A1 (en) 2025-07-24
TW202027738A (zh) 2020-08-01
EP3865130A4 (en) 2022-07-20
JP2022504760A (ja) 2022-01-13
KR20210076951A (ko) 2021-06-24
MX2021004151A (es) 2021-09-08
SG11202103707TA (en) 2021-05-28
JP7513286B2 (ja) 2024-07-09
CN113164438A (zh) 2021-07-23
CN120168498A (zh) 2025-06-20
EP3865130A1 (en) 2021-08-18
IL282228B1 (en) 2026-07-01
CA3115869A1 (en) 2020-04-16
WO2020074010A1 (zh) 2020-04-16
AU2019357933B2 (en) 2023-11-23

Similar Documents

Publication Publication Date Title
US20180085341A1 (en) Methods for treating cancer
US20190224157A1 (en) Methods for treating cancer
US20180250261A1 (en) Method for treating cancer with a stat3 pathway inhibitor and kinase inhibitor
US20180333385A1 (en) Methods for treating cancer
KR20180006919A (ko) 암의 치료 방법
US20250235425A1 (en) New Combination Solution for Treating Chemotherapy Refractory Cancer
WO2016168858A1 (en) Methods for treating cancer
HK40124738A (zh) 治疗化疗难治性癌症的新联合用药方案
HK40048413A (en) New combination solution for treating chemotherapy refractory cancer
HK40047114A (en) New combination solution for treating chemotherapy refractory cancer
EA046190B1 (ru) Новое комбинированное решение для лечения рака, резистентного к химиотерапии

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)